Targeted Delivery of Immunoliposomal Doxorubicin to B-lymphoid Cells via Anti-CD19 Monoclonal Antibodies and Fragments

摘要

In our continuing efforts to develop targeted therapies for human B cell malignancies, the in vitro binding and cytotoxicity, and the pharmacokinetics/biodistribution and therapeutics Was compared for doxorubicin-loaded immunoliposomes targeted via three different anti-CD 19 constructs: the anti-CD19 HD37 whole monoclonal antibody, its Fab' fragment or its single chain Fv (scFv).